Revolutionising cellular therapies for cancer and beyond

We’re developing more precise and more accessible treatment options for patients with solid cancers, endometriosis and Alzheimer’s disease

Pioneering excellence in the field of immunotherapy

Cartherics creates precisely-defined immunotherapy treatments to combat a variety of cancers, endometriosis and Alzheimer’s disease. We combine the best components of immune targeting utilising gene editing and CAR technology to advance cell therapy to provide more diverse off-the-shelf treatments for patients. Our team has strong backgrounds in research, development, and product commercialisation. And we partner with leading commercial and academic groups with complementary technology to push the boundaries of cell therapy for cancer and beyond.

Learn more about us

Some of our partners

Latest news

Life Science Success podcast with Prof. Alan Trounson

By Christine Filippis / October 20, 2023
Cartherics’ CEO, Prof. Alan Trounson, was recently a guest on Life Science Success podcast. Hosted by Dr Don Davies, this...
Read More

Cartherics appoints new Chief Scientific Officer

By Christine Filippis / October 17, 2023
Melbourne, Australia, 17 October 2023 –  Cartherics Pty Ltd (“Cartherics” or “Company”), a biotechnology company developing immune cell therapies for...
Read More

Ovarian cancer is not ovarian cancer

By Christine Filippis / October 3, 2023
Cartherics’ Dr Ian Nisbet (Chief Operating Officer) and Kathy Skoff (Clinical Trials Manager) recently attended an ovarian cancer symposium in...
Read More